Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4FRONT-2: Phase 3 trial of single intravitreal 4D-150 versus aflibercept in neovascular age-related macular degeneration
MOH_2025-12-16_015547Phase 3Not yet recruiting
- Sponsor
- 4D Molecular Therapeutics
- Start
- Nov 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics, Gene Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in exudative macular degeneration and macular neovascularization (MNV) comparing 4D-150 study treatment with Active control with Eylea (2 arms). Primary endpoints: Primary efficacy endpoint and Primary objective. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
4D-150aflibercept
03
Conditions
exudative macular degenerationmacular neovascularization (MNV)
Beyond the preview
Go deeper on MOH_2025-12-16_015547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-12-16_015547.